key: cord-1048232-la3rjxhh
authors: Niemann, Carsten U; da Cunha-Bang, Caspar; Helleberg, Marie; Ostrowski, Sisse Rye; Brieghel, Christian
title: Patients with CLL have lower risk of death from COVID-19 in the omicron era.
date: 2022-05-21
journal: Blood
DOI: 10.1182/blood.2022016147
sha: dd65c35f6ed2bc69d98404e57cc1e283d184427c
doc_id: 1048232
cord_uid: la3rjxhh

Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and corona virus disease 2019 (COVID-19) have high mortality rates. Infection with the omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients have not previously been reported. In a cohort of patients with CLL tested for severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the omicron variant, rates of hospitalizations and ICU-admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contactss and in particular those above 70 years of age with one or more comorbidities should be considered for closer monitoring and pre-emptive antiviral therapy upon a positive SARS-CoV-2 test.

Patients with chronic lymphocytic leukemia (CLL) have increased morbidity and mortality following infection with severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to coronavirus disease 2019 . 1, 2 The immune dysfunction inherent to CLL itself and CLL treatment whether targeted or chemoimmunotherapy based, is considered the likely cause of increased susceptibility to severe COVID-19. 3 During the first and second pandemic wave, most CLL patients with COVID-19 developed severe disease and the 30-day mortality was 31-50% for those admitted, while one study indicates improved survival for patients with CLL upon COVID-19 later in the pandemic. 1, 2, 4 Further, patients with CLL demonstrated impaired vaccination response in terms of ability to produce neutralizing anti-SARS-CoV-2 antibodies, while the T-cell response was also impaired for part of the populations. [5] [6] [7] [8] Data on outcome upon infection with SARS-CoV-2 B.1.1.529 (omicron) variant is warranted for immunocompromised patients in general and for patients with CLL in particular. 9 The first Danish omicron case was detected on 25 th Nov 2021. The variant became dominant in Denmark by 17 th Dec 2021, enabling high levels of break-through infections among vaccinated individuals. 10 In Denmark, all patients diagnosed with a hematological malignancy were offered third and fourth booster vaccination against SARS-CoV-2 in August 2021 and January 2022, respectively. At the same time, a single dose of anti-SARS-CoV-2 monoclonal antibody (mAb) was recommended for immunocompromised patients testing positive for SARS-CoV-2 with sotrovimab being the most widely used mAb in Denmark, while the standard of care for immunocompromised patients admitted with moderate to severe COVID-19 was dexamethasone, low molecular weight heparin and remdesivir. 11, 12 Remdesivir was widely used for hematological patients regardless of disease severity since approval mid-2020. 13, 14 Sotrovimab retained its neutralizing activities against the omicron BA.1 sublineage, but recently, in vitro studies have shown reduced activity against the BA.2 sublineage. 15 16 Methods Insights into potential variation in clinical outcome for immunocompromised patients upon infection with the omicron variant is limited. Here we investigated the rate of hospitalization, admission to intensive care unit (ICU) and mortality following infection with SARS-CoV-2 among patients with CLL in a Danish cohort with SARS-CoV-2 PCR test from electronic health records (EHR) between March 2020 through January 2022 (EHR cohort). Additionally, we analyzed a cohort of patients registered with a diagnosis of CLL in the Danish CLL registry 17 for whom a positive SARS-CoV-2 PCR test was identified through the PERSIMUNE treatment database with microbiology data retrieved as previously described (population cohort). 18 19 We included all patients with a CLL diagnosis (ICD10 code DC91.1) and a positive PCR for SARS-CoV-2 within the EHR (EHR cohort). The population cohort initiates in September 2020, the time of introducing widespread testing outside the EHR. Patients with multiple positive PCR tests more than 12 weeks apart were considered as having reinfection. Baseline characteristics were stratified by timeperiod of first positive SARS-CoV-2 PCR test (Table 1) . Primary outcomes were time to hospital admission, time to ICU admission and 30-day mortality. We followed patients from date of first positive PCR until event, death or date of last follow-up (22 nd February 2022 and 15 th March 2022 for the EHR and population cohort, respectively). The study was approved by the Ethics Committee and Data Protection Agency.

Until 28 th January 2022, 151 patients with CLL had 153 COVID-19 infections confirmed with a positive PCR test for SARS-CoV-2 in the EHR system for Eastern Denmark (EHR cohort). Two reinfections were identified with positive PCR tests more than a year apart. Additionally, we identified 640 patients within the Danish CLL registry with a positive SARS-CoV-2 PCR test outside the EHR system (population cohort). No reinfections in terms of patients with positive PCR tests more than 12 weeks apart were identified within this cohort (patients within the EHR cohort were excluded from the population cohort). Stratified by period, 59, 40, 32, and 22 patients in the EHR cohort were first PCR positive in time periods 1 to 4, respectively. In the population cohort, 24, 66, 73 and 477 patients were first PCR positive in periods 1 to 4, respectively. There were no significant differences in baseline characteristics between the four periods, but patients in the EHR cohort were significantly older compared with patients in the population cohort (P = .0052) even though the patients in the EHR cohort were also diagnosed with CLL significantly more recently ( ( Table 1 ; P = .024). At least 43 of 109 (39%) and 190 of 640 (30%) patients in the EHR and population cohort, respectively, had received CLL therapy prior to testing positive for SARS-CoV-2 (P=.054. For the EHR cohort, the rate of hospitalizations for patients with CLL testing positive for SARS-CoV-2 was significantly higher (>75%) during the second period compared with periods 3 (omicron emergence) and 4 (omicron dominance), where preemptive mAb were administered during hospital admissions for patients with CLL upon a positive SARS-CoV-2 PCR test ( Figure 1A; P<.014). During period 3 and 4, mAb were administered at outpatient visits, which likely explains the lower 30-day admission rates (56-60% vs 83%). ICU admission rates were highest prior to emergence of omicron (12-12.5% vs 0-3%, Figure 1B ), which may reflect impact of a third and fourth booster vaccine, improved care for patients with COVID-19 and differences in severity between SARS-CoV-2 variants. 11, 12, 20 The ICU admission rates were lower than previously reported in international cohorts of COVID-19 in CLL (26% to 37% for hospitalized patients). 1,2 This could be due to the full implementation of early treatment with mAb, almost universal treatment with remdesivir for hospitalized patients without renal failure and high vaccination rates and administration of up to 30 L/min oxygen outside the ICU in Denmark.

For the EHR cohort, 30-day overall survival (OS) was above 75% in all four periods (77-91%, Figure   1C ). Despite representing a cohort with close hospital connection (EHR cohort), these survival rates are slightly better than the previously reported OS rates for COVID-19 in CLL during the first part of the pandemic (64-73%); although one study reported a higher OS rate of 89% for CLL patients testing positive for SARS-CoV-2 after 1 st May 2020. 1,2 Five out of six fatal cases (including deaths after 30 days) in period 3 were infected with the delta variant (missing variant information for the last case, data not shown). The five patients who died within 30 days of a positive SARS-CoV-2 test in period 4 were aged above 71 years and all had comorbidities, e.g. dementia, other malignant diseases, diabetes, cardiac and pulmonary comorbidities. Four of the five fatal cases had confirmed omicron variant, while variant data were missing for the last case. Three of the five patients died from respiratory failure while two patients died at home without known cause of death. Two of the fatal cases received mAb and dexamethasone, one of them also remdesivir; the three remaining fatal cases did not receive COVID-19 specific treatment. To assess whether the EHR cohort was biased towards patients with more severe COVID-19 and/or CLL disease, we next identified the population cohort who tested PCR positive for SARS-CoV-2 outside the EHR system.

Only OS could be assessed for this population. Gradually improving 30-days survival rates were demonstrated from periods 2 through 4 (93.9%, 94.5% and 99.2%, respectively; no deaths were seen in time period 1 which started 16 September 2020 with mass testing; P<.002; pairwise logrank, Figure 1D ). When combining the two cohorts, 30-day OS rates gradually improved from periods 1 through 4 (88.0%, 89.6%, 93.3% and 98.2%, respectively) with a significantly higher OS in the omicron BA.2 period compared with periods 1-3 (P≤.0077; pairwise log-rank, Figure 1E ).

Limitations apply to this study; the size of the EHR patient population was limited, patients with CLL testing positive for SARS-CoV-2 outside EHR test sites were only included in the population cohort. Thus, the improved outcome in the population cohort may reflect less severe CLL, less severe COVID-19 and/or less comorbidity.

Based on epidemiological data from South Africa, 21 

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Targeting the tumor microenvironment in chronic lymphocytic leukemia

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in

Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Remdesivir for the Treatment of Covid-19 -Final Report

Dexamethasone in Hospitalized Patients with Covid-19

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting